Macrophage immunoregulatory pathways in tuberculosis

Seminars in Immunology

Volumn 26, Issue 6, 2014, Pages 471-485

  Rajaram, Murugesan V S ^a   Ni, Bin ^a   Dodd, Claire E ^a   Schlesinger, Larry S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Innate immunity; Lung; Macrophages; MicroRNAs; Pattern recognition receptors

Indexed keywords

BCG VACCINE; CYTOKINE; DECTIN 1; DECTIN 2; DNA VACCINE; GAMMA INTERFERON; HYDROLASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; LECTIN; LIVER X RECEPTOR; LUNG SURFACTANT; MANNOSE RECEPTOR; MICRORNA; MINCLE; PATTERN RECOGNITION RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SCAVENGER RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AIRBORNE BACTERIUM; ANTIGEN PRESENTING CELL; CYTOKINE RESPONSE; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LIPID METABOLISM; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MACROPHAGE; MACROPHAGE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; REVIEW; TH2 CELL; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; LUNG; MICROBIOLOGY; PATHOLOGY;

CYTOKINES; GENE EXPRESSION REGULATION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MICRORNAS; MYCOBACTERIUM TUBERCULOSIS; RECEPTORS, PATTERN RECOGNITION; TUBERCULOSIS, PULMONARY;

EID: 84919973536     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2014.09.010     Document Type: Review

References (310)

1. Guirado E., Schlesinger L.S., Kaplan G. Macrophages in tuberculosis: friend or foe. Semin Immunopathol 2013, 35:563-583.
2. Verrall A.J., Netea M.G., Alisjahbana B., Hill P.C., van C.R. Early clearance of Mycobacterium tuberculosis: a new frontier in prevention. Immunology 2014, 141:506-513.
3. Cooper A.M. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009, 27:393-422.
4. Berrington W.R., Hawn T.R. Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter. Immunol Rev 2007, 219:167-186.
5. Bhatt K., Salgame P. Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol 2007, 27:347-362.
6. Parasa V.R., Rahman M.J., Ngyuen Hoang A.T., Svensson M., Brighenti S., Lerm M. Modeling Mycobacterium tuberculosis early granuloma formation in experimental human lung tissue. Dis Model Mech 2014, 7:281-288.
7. Hussell T., Bell T.J. Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014, 14:81-93.
8. Galli S.J., Borregaard N., Wynn T.A. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol 2011, 12:1035-1044.
9. Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014, 6:13.
10. Murray P.J., Allen J.E., Biswas S.K., Fisher E.A., Gilroy D.W., Goerdt S., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
11. Day J., Friedman A., Schlesinger L.S. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc Natl Acad Sci U S A 2009, 106:11246-11251.
12. Rajaram M.V., Brooks M.N., Morris J.D., Torrelles J.B., Azad A.K., Schlesinger L.S. Mycobacterium tuberculosis activates human macrophage peroxisome proliferator-activated receptor gamma linking mannose receptor recognition to regulation of immune responses. J Immunol 2010, 185:929-942.
13. Verreck F., De Boer T., Langenberg D.M., Hoeve M., Kramer M., Vaisberg E., et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 3-30-2004, 101(13):4560-4565.
14. Leemans J.C., Juffermans N.P., Florquin S., Van Rooijen N., Vervoordeldonk M.J., Verbon A., et al. Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 2001, 166:4604-4611.
15. Kahnert A., Seiler P., Stein M., Bandermann S., Hahnke K., Mollenkopf H., et al. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur J Immunol 2006, 36:631-647.
16. Nicholson S., da Gloria M., Bonecini-Almeida M.D.G., Silva J.R.L.E., Nathan C., Xie Q.W., et al. Inducible nitric oxide synthase in pulmonary alveolar macrophages from patients with tuberculosis. J Exp Med 1996, 183:2293-2302.
17. Small P.M., Fujiwara P.I. Management of tuberculosis in the United States. N Engl J Med 2001, 345:189-200.
18. Creuwels L.A., van Golde L.M., Haagsman H.P. The pulmonary surfactant system: biochemical and clinical aspects. Lung 1997, 175:1-39.
19. Mason R.J. Biology of alveolar type II cells. Respirology 2006, 11(Suppl.):S12-S15.
20. Arcos J., Sasindran S.J., Fujiwara N., Turner J., Schlesinger L.S., Torrelles J.B. Human lung hydrolases delineate Mycobacterium tuberculosis-macrophage interactions and the capacity to control infection. J Immunol 2011, 187:372-381.
21. Carlson T.K., Brooks M., Meyer D., Henning L., Murugesan V., et al. Pulmonary innnate immunity: soluble and cellular host defenses of the lung. Regulation of innate immune function 2010, 165-211. Transworld Research Network. C. Marsh, S. Tridandapani, P.M. Kerala (Eds.).
22. Ferguson J.S., Voelker D.R., McCormack F.X., Schlesinger L.S. Surfactant protein D binds to Mycobacterium tuberculosis bacili and lipoarrabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages. J Immunol 1999, 163:312-321.
23. Ferguson J.S., Martin J.L., Azad A.K., McCarthy T.R., Kang P.B., Voelker D.R., et al. Surfactant protein D increases fusion of Mycobacterium tuberculosis-containing phagosomes with lysosomes in human macrophages. Infect Immun 2006, 74:7005-7009.
24. Kang P.B., Azad A.K., Torrelles J.B., Kaufman T.M., Beharka A., Tibesar E., et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 2005, 202:987-999.
25. Torrelles J.B., Azad A.K., Schlesinger L.S. Fine discrimination in the recognition of individual species of phosphatidyl-myo-inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition receptors. J Immunol 2006, 177:1805-1816.
26. Weikert L.F., Lopez J.P., Abdolrasulnia R., Chroneos Z.C., Shephert V.L. Surfactant protein A enhances mycobacterial killing by rat macrophages through a nitric oxide-dependent pathway. Am J Physiol Lung Cell Mol Physiol 2000, 279:L216-L223.
27. Borron P., McCormack F.X., Elhalwagi B.M. Surfactant protein A inhibits T cell proliferation via its collagen-like tail and a 210-kDa receptor. Am J Physiol 1998, 275:L679-L686.
28. Wright J.R., Borron P., Brinker K.G., Folz R.J. Surfactant protein A. Regulation of innate and adaptive immune responses in lung inflammation. Am J Respir Cell Mol Biol 2001, 24:513-517.
29. Weikert L.F., Edwards K., Chroneos Z.C., Hager C., Hoffman L., Shepherd V.L. SP-A enhances uptake of bacillus Calmette-Guerin by macrophages through a specific SP-A receptor. Am J Physiol Lung Cell Mol Physiol 1997, 272:L989-L995.
30. Hansen S., Lo B., Evans K., Neophytou P., Holmskov U., Wright J.R. Surfactant protein D augments bacterial association but attenuates major histocompatibility complex class II presentation of bacterial antigens. Am J Respir Cell Mol Biol 2007, 36:94-102.
31. Senft A.P., Korfhagen T.R., Whitsett J.A., Shapiro S.D., LeVine A.M. Surfactant protein-D regulates soluble CD14 through matrix metalloproteinase-12. J Immunol 2005, 174:4953-4959.
32. Wu H., Kuzmenko A., Wan S., Schaffer L., Weiss A., Fisher J.H., et al. Surfactant proteins A and D inhibit the growth of Gram-negative bacteria by increasing membrane permeability. J Clin Invest 2003, 111:1589-1602.
33. Guilliams M., Lambrecht B.N., Hammad H. Division of labor between lung dendritic cells and macrophages in the defense against pulmonary infections. Mucosal Immunol 2013, 6:464-473.
34. Hasenberg M., Stegemann-Koniszewski S., Gunzer M. Cellular immune reactions in the lung. Immunol Rev 2013, 251:189-214.
35. Wright J.R. Immunomodulatory functions of surfactant. Physiol Rev 1997, 77:931-962.
36. Mason R.J., Voelker D.R. Regulatory mechanisms of surfactant secretion. Biochim Biophys Acta 1998, 1408:226-240.
37. Wright J.R. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005, 5:58-68.
38. Crouch E., Wright J.R. Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol 2001, 63:521-554.
39. Van Iwaarden J.F., Van Strijp J.A.G., Visser H., Haagsman H.P., Verhoef J., van Golde L.M.G. Binding of surfactant protein A (SP-A) to herpes simplex virus type 1-infected cells is mediated by the carbohydrate moiety of SP-A. J Biol Chem 1992, 267:25039-25043.
40. Hickling T.P., Malhotra R., Bright H., McDowell W., Blair E.D., Sim R.B. Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells. Viral Immunol 2000, 13:125-135.
41. van Iwaarden F., Welmers B., Verhoef J., Haagsman H.P., Van Golde L.M.G. Pulmonary surfactant protein A enhances the host-defense mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990, 2:91-98.
42. Haagsman H.P. Interactions of surfactant protein A with pathogens. Biochim Biophys Acta 1998, 1408:264-277.
43. Downing J.F., Pasula R., Wright J.R., Twigg H.L., Martin W.J. Surfactant protein A promotes attachment of Mycobacterium tuberculosis to alveolar macrophages during infection with human immunodeficiency virus. Proc Natl Acad Sci U S A 1995, 92:4848-4852.
44. Gaynor C.D., McCormack F.X., Voelker D.R., McGowan S.E., Schlesinger L.S. Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J Immunol 1995, 155:5343-5351.
45. Pasula R., Downing J.F., Wright J.R., Kachel D.L., Davis T.E., Martin W.J. Surfactant protein A (SP-A) mediates attachment of Mycobacterium tuberculosis to murine alveolar macrophages. Am J Respir Cell Mol Biol 1997, 17:209-217.
46. Sidobre S., Nigou J., Puzo G., Riviere M. Lipoglycans are putative ligands for the human pulmonary surfactant protein A attachment to mycobacteria. J Biol Chem 2000, 275:2415-2422.
47. Beharka A.A., Gaynor C.D., Kang B.K., Voelker D.R., McCormack F.X., Schlesinger L.S. Pulmonary surfactant protein A up-regulates activity of the mannose receptor, a pattern recognition receptor expressed on human macrophages. J Immunol 2002, 169:3565-3573.
48. Crowther J.E., Kutala V.K., Kuppusamy P., Ferguson J.S., Beharka A.A., Zweier J.L., et al. Pulmonary surfactant protein a inhibits macrophage reactive oxygen intermediate production in response to stimuli by reducing NADPH oxidase activity. J Immunol 2004, 172:6866-6874.
49. Nguyen H.A., Rajaram M.V., Meyer D.A., Schlesinger L.S. Pulmonary surfactant protein A and surfactant lipids upregulate IRAK-M, a negative regulator of TLR-mediated inflammation in human macrophages. Am J Physiol Lung Cell Mol Physiol 2012, 303:L608-L616.
50. Ferguson J.S., Voelker D.R., Ufnar J.A., Schlesinger L.S. Surfactant protein D inhibition of human macrophage uptake of Mycobacterium tuberculosis is indepenndent of bacterial agglutination. J Immunol 2002, 168:1309-1314.
51. Hook G.E. Extracellular hydrolases of the lung. Biochemistry 1978, 17:520-528.
52. Hook G.E., Gilmore L.B. Hydrolases of pulmonary lysosomes and lamellar bodies. J Biol Chem 1982, 257:9211-9220.
53. Erwig L.P., Kluth D.C., Walsh G.M., Rees A.J. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 1998, 161:1983-1988.
54. Stout R.D., Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol 2004, 76:509-513.
55. Porcheray F., Viaud S., Rimaniol A.C., Leone C., Samah B., reuddre-Bosquet N., et al. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol 2005, 142:481-489.
56. Mosser D.M. The many faces of macrophage activation. J Leukoc Biol 2003, 73:209-212.
57. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
58. Ezekowitz R.A.B., Austyn J., Stahl P.D., Gordon S. Surface properties of bacillus Calmette-Guerin-activated mouse macrophages: reduced expression of mannose-specific endocytosis, Fc receptors, and antigen F4/80 accompanies induction of Ia. J Exp Med 1981, 154:60-76.
59. Geissmann F., Gordon S., Hume D.A., Mowat A.M., Randolph G.J. Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010, 10:453-460.
60. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
61. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
62. Gordon S. Macrophage heterogeneity and tissue lipids. J Clin Invest 2007, 117:89-93.
63. Gordon S., Fraser I., Nath D., Hughes D., Clarke S. Macrophages in tissues and in vitro. Curr Opin Immunol 1992, 4:25-32.
64. Linehan S.A., Martinez-Pomares L., Gordon S. Macrophage lectins in host defence. Microbes Infect 2000, 2:279-288.
65. Martinez-Pomares L., Mahoney J.A., Kaposzta R., Linehan S.A., Stahl P.D., Gordon S. A functional soluble form of the murine mannose receptor is produced by macrophages in vitro and is present in mouse serum. J Biol Chem 1998, 273:23376-23380.
66. Fang F.C., Vazquez-Torres A. Nitric oxide production by human macrophages: there's NO doubt about it. Am J Physiol Lung Cell Mol Physiol 2002, 282:L941-L943.
67. Varin A., Gordon S. Alternative activation of macrophages: immune function and cellular biology. Immunobiology 2009, 214:630-641.
68. Salgame P., Yap G.S., Gause W.C. Effect of helminth-induced immunity on infections with microbial pathogens. Nat Immunol 2013, 14:1118-1126.
69. Schreiber T., Ehlers S., Heitmann L., Rausch A., Mages J., Murray P.J., et al. Autocrine IL-10 induces hallmarks of alternative activation in macrophages and suppresses antituberculosis effector mechanisms without compromising T cell immunity. J Immunol 2009, 183:1301-1312.
70. Geiser M. Update on macrophage clearance of inhaled micro- and nanoparticles. J Aerosol Med Pulm Drug Deliv 2010, 23:207-217.
71. Stone K.C., Mercer R.R., Gehr P., Stockstill B., Crapo J.D. Allometric relationships of cell numbers and size in the mammalian lung. Am J Respir Cell Mol Biol 1992, 6:235-243.
72. Stone K.C., Mercer R.R., Freeman B.A., Chang L.Y., Crapo J.D. Distribution of lung cell numbers and volumes between alveolar and nonalveolar tissue. Am Rev Respir Dis 1992, 146:454-456.
73. Blusse Van Out Alblas A., Van Furth R. Origin, kinetics, and characteristics of pulmonary macrophages in the normal steady state. J Exp Med 1979, 149:1504-1518.
74. Aberdein J.D., Cole J., Bewley M.A., Marriott H.M., Dockrell D.H. Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol 2013, 174:193-202.
75. Davies L.C., Rosas M., Smith P.J., Fraser D.J., Jones S.A., Taylor P.R. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. Eur J Immunol 2011, 41:2155-2164.
76. Snelgrove R.J., Goulding J., Didierlaurent A.M., Lyonga D., Vekaria S., Edwards L., et al. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008, 9:1074-1083.
77. Gao X., Dong Y., Liu Z., Niu B. Silencing of triggering receptor expressed on myeloid cells-2 enhances the inflammatory responses of alveolar macrophages to lipopolysaccharide. Mol Med Rep 2013, 7:921-926.
78. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003, 3:445-453.
79. Janssen W.J., McPhillips K.A., Dickinson M.G., Linderman D.J., Morimoto K., Xiao Y.Q., et al. Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am J Respir Crit Care Med 2008, 178:158-167.
80. Fels A., Cohn Z.A. The alveolar macrophage. J Appl Physiol 1986, 60:353-369.
81. Arias M., Zabaleta J., Rodriguez J.I., Rojas M., Paris S.C., Garcia L.F. Failure to induce nitric oxide production by human monocyte-derived macrophages. Manipulation of biochemical pathways. Allergol Immunopathol (Madr) 1997, 25:280-288.
82. Greening A.P., Lowrie D.B. Extracellular release of hydrogen peroxide by human alveolar macrophages: the relationship to cigarette smoking and lower respiratory tract infections. Clin Sci (Lond) 1983, 65:661-664.
83. MacMicking J.D., North R.J., LaCourse R., Mudgett J.S., Shah S.K., Nathan C.F. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A 1997, 94:5243-5248.
84. MacMicking J.D. Recognizing macrophage activation and host defense. Cell Host Microbe 2009, 5:405-407.
85. Scanga C.A., Bafica A., Feng C.G., Cheever A.W., Hieny S., Sher A. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect Immun 2004, 72:2400-2404.
86. Reece S.T., Loddenkemper C., Askew D.J., Zedler U., Schommer-Leitner S., Stein M., et al. Serine protease activity contributes to control of Mycobacterium tuberculosis in hypoxic lung granulomas in mice. J Clin Invest 2010, 120:3365-3376.
87. Herbst S., Schaible U.E., Schneider B.E. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS ONE 2011, 6:e19105.
88. phox-/- mice. Infect Immun 2000, 68:1231-1234.
89. Chelen C.J., Fang Y., Freeman G.J., Secrist H., Marshall J.D., Hwang P.T., et al. Human alveolar macrophages present antigen ineffectively due to defective expression of B7 costimulatory cell surface molecules. J Clin Invest 1995, 95:1415-1421.
90. Holt P.G., Oliver J., Bilyk N., McMenamin C., McMenamin P.G., Kraal G., et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993, 177:397-407.
91. Johansson A., Lundborg M., Sköld C.M., Lundahl J., Tornling G., Eklund A., et al. Functional, morphological, and phenotypical differences between rat alveolar and interstitial macrophages. Am J Respir Cell Mol Biol 1997, 16:582-588.
92. Schneberger D., Aharonson-Raz K., Singh B. Pulmonary intravascular macrophages and lung health: what are we missing. Am J Physiol Lung Cell Mol Physiol 2012, 302:L498-L503.
93. Cai Y., Sugimoto C., Arainga M., Alvarez X., Didier E.S., Kuroda M.J. In vivo characterization of alveolar and interstitial lung macrophages in rhesus macaques: implications for understanding lung disease in humans. J Immunol 2014, 192:2821-2829.
94. Aderem A., Underhill D.M. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999, 17:593-623.
95. Yamamoto M., Takeda K., Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 2004, 40:861-868.
96. Cambi A., Koopman M., Figdor C.G. How C-type lectins detect pathogens. Cell Microbiol 2005, 7:481-488.
97. Janssens S., Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003, 16:637-646.
98. Juarez E., Nunez C., Sada E., Ellner J.J., Schwander S.K., Torres M. Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res 2010, 11:2.
99. Suzuki K., Suda T., Naito T., Ide K., Chida K., Nakamura H. Impaired toll-like receptor 9 expression in alveolar macrophages with no sensitivity to CpG DNA. Am J Respir Crit Care Med 2005, 171:707-713.
100. Brightbill H.D., Libraty D.H., Krutzik S.R., Yang R.-B., Belisle J.T., Bleharski J.R., et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999, 285:732-736.
101. Drage M.G., Pecora N.D., Hise A.G., Febbraio M., Silverstein R.L., Golenbock D.T., et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol 2009, 258:29-37.
102. Abel B., Thieblemont N., Quesniaux V.J., Brown N., Mpagi J., Miyake K., et al. Toll-like receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice. J Immunol 2002, 169:3155-3162.
103. Jung S.B., Yang C.S., Lee J.S., Shin A.R., Jung S.S., Son J.W., et al. The mycobacterial 38-kilodalton glycolipoprotein antigen activates the mitogen-activated protein kinase pathway and release of proinflammatory cytokines through Toll-like receptors 2 and 4 in human monocytes. Infect Immun 2006, 74:2686-2696.
104. Bafica A., Scanga C.A., Feng C.G., Leifer C., Cheever A., Sher A. TLR9 regulates Th1 responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005, 202:1715-1724.
105. Wileman T.E., Lennartz M.R., Stahl P.D. Identification of the macrophage mannose receptor as a 175-kDa membrane protein. Proc Natl Acad Sci USA 1986, 83:2501-2505.
106. McGreal E.P., Miller J.L., Gordon S. Ligand recognition by antigen-presenting cell C-type lectin receptors. Curr Opin Immunol 2005, 17:18-24.
107. Stahl P.D., Ezekowitz R.A. The mannose receptor is a pattern recognition receptor involved in host defense. Curr Opin Immunol 1998, 10:50-55.
108. Stahl P.D. The macrophage mannose receptor: current status. Am J Respir Cell Mol Biol 1990, 2:317-318.
109. Speert D.P., Silverstein S.C. Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan. J Leukocyte Biol 1985, 38:655-658.
110. Lee S.J., Evers S., Roeder D., Parlow A.F., Risteli J., Risteli L., et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 2002, 295:1901.
111. Medzhihtov R., Janeway C. Innate Immunity. N Engl J Med 2000, 343:338-344.
112. Torrelles J.B., Schlesinger L.S. Diversity in Mycobacterium tuberculosis mannosylated cell wall determinants impacts adaptation to the host. Tuberculosis (Edinb) 2010, 90:84-93.
113. Fenton M.J., Riley L.W., Schlesinger L.S. Receptor-mediated recognition of Mycobacterium tuberculosis by host cells. Tuberculosis and the tubercle bacillus 2005, 405-426. ASM Press, New York. S.T. Cole, K.D. Eisenach, D.N. McMurray, W.R. Jacobs (Eds.).
114. Schlesinger L.S., Kaufman T.M., Iyer S., Hull S.R., Marciando L.K. Differences in mannose receptor-mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by human macrophages. J Immunol 1996, 157:4568-4575.
115. Schlesinger L.S., Hull S.R., Kaufman T.M. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J Immunol 1994, 152:4070-4079.
116. Siddiqui M.R., Meisner S., Tosh K., Balakrishnan K., Ghei S., Fisher S.E., et al. A major susceptibility locus for leprosy in India maps to chromosome 10p13. Nat Genet 2001, 27:439-441.
117. Mira M.T., Alcais A., Van T.N., Thai V.H., Huong N.T., Ba N.N., et al. Chromosome 6q25 is linked to susceptibility to leprosy in a Vietnamese population. Nat Genet 2003, 33:412-415.
118. Tosh K., Meisner S., Siddiqui M.R., Balakrishnan K., Ghei S., Golding M., et al. A region of chromosome 20 is linked to leprosy susceptibility in a South Indian population. J Infect Dis 2002, 186:1190-1193.
119. Zhang X., Jiang F., Wei L., Li F., Liu J., Wang C., et al. Polymorphic allele of human MRC1 confer protection against tuberculosis in a Chinese population. Int J Biol Sci 2012, 8:375-382.
120. Alter A., de L.L., Van T.N., Thai V.H., Huong N.T., Ba N.N., et al. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet 2010, 127:337-348.
121. Martínez-Pomares L., Kosco-Vilbois M., Darley E., Tree P., Herren S., Bonnefoy J.Y., et al. Fe chimeric protein containing the cysteine-rich domain of the murine mannose receptor binds to macrophages from splenic marginal zone and lymph node subcapsular sinus and to germinal centers. J Exp Med 1996, 184:1927-1937.
122. Linehan S.A., Martiniz-Pomares L., Stahl P.D., Gordon S. Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: in situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med 1999, 189:1961-1972.
123. Engering A.J., Cella M., Fluitsma D.M., Hoefsmit E.C., Lanzavecchia A., Pieters J. Mannose receptor mediated antigen uptake and presentation in human dendritic cells. Adv Exp Med Biol 1997, 417:183-187.
124. Tan M.C., Mommaas A.M., Drijfhout J.W., Jordens R., Onderwater J.J., Verwoerd D., et al. Mannose receptor mediated uptake of antigens strongly enhances HLA-class II restricted antigen presentation by cultured dendritic cells. Adv Exp Med Biol 1997, 417:171-174.
125. Berney C., Herren S., Power C.A., Gordon S., Martinez-Pomares L., Kosco-Vilbois M.H. A member of the dendritic cell family that enters B cell follicles and stimulates primary antibody responses identified by a mannose receptor fusion protein. J Exp Med 1999, 190:851-860.
126. Prigozy T.I., Sieling P.A., Clemens D., Stewart P.L., Behar S.M., Porcelli S.A., et al. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Immunity 1997, 6:187-197.
127. Burgdorf S., Kautz A., Bohnert V., Knolle P.A., Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007, 316:612-616.
128. Hattori Y., Kawakami S., Lu Y., Nakamura K., Yamashita F., Hashida M. Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. J Gene Med 2006, 8:824-834.
129. Lu Y., Kawakami S., Yamashita F., Hashida M. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 2007, 28:3255-3262.
130. Azad A.K., Rajaram M.V., Schlesinger L.S. Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics. J Cytol Mol Biol 2014, 1. 10.13188/2325-4653.1000003.
131. McNally A.K., DeFife K.M., Anderson J.M. Interleukin-4-induced macrophage fusion is prevented by inhibitors of mannose receptor activity. Am J Pathol 1996, 149:975-985.
132. Gordon S., Keshav S., Stein M. BCG-induced granuloma formation in murine tissues. Immunobiology 1994, 191:369-377.
133. Moore K.J., Freeman M.W. Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006, 26:1702-1711.
134. Canton J., Neculai D., Grinstein S. Scavenger receptors in homeostasis and immunity. Nat Rev Immunol 2013, 13:621-634.
135. Zimmerli S., Edwards S., Ernst J.D. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am J Respir Cell Mol Biol 1996, 15:760-770.
136. Doi T., Higashino K., Kurihara Y., Wada Y., Miyazaki T., Nakamura H., et al. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. J Biol Chem 1993, 268:2126-2133.
137. Yamamoto K., Nishimura N., Doi T., Imanishi T., Kodama T., Suzuki K., et al. The lysine cluster in the collagen-like domain of the scavenger receptor provides for its ligand binding and ligand specificity. FEBS Lett 1997, 414:182-186.
138. Arredouani M.S., Palecanda A., Koziel H., Huang Y.C., Imrich A., Sulahian T.H., et al. MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. J Immunol 2005, 175:6058-6064.
139. Bowdish D.M., Sakamoto K., Kim M.J., Kroos M., Mukhopadhyay S., Leifer C.A., et al. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog 2009, 5:e1000474.
140. Arredouani M., Yang Z., Ning Y., Qin G., Soininen R., Tryggvason K., et al. The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J Exp Med 2004, 200:267-272.
141. Arredouani M.S., Yang Z., Imrich A., Ning Y., Qin G., Kobzik L. The macrophage scavenger receptor SR-AI/II and lung defense against pneumococci and particles. Am J Respir Cell Mol Biol 2006, 35:474-478.
142. Hollifield M., Bou G.E., de Villiers W.J., Garvy B.A. Scavenger receptor A dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii. Infect Immun 2007, 75:3999-4005.
143. Asada K., Sasaki S., Suda T., Chida K., Nakamura H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 2004, 169:195-200.
144. Reddy R.C. Immunomodulatory role of PPAR-gamma in alveolar macrophages. J Investig Med 2008, 56:522-527.
145. Mahajan S., Dkhar H.K., Chandra V., Dave S., Nanduri R., Janmeja A.K., et al. Mycobacterium tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARgamma and TR4 for survival. J Immunol 2012, 188:5593-5603.
146. Hawkes M., Li X., Crockett M., Diassiti A., Finney C., Min-Oo G., et al. CD36 deficiency attenuates experimental mycobacterial infection. BMC Infect Dis 2010, 10:299.
147. Court N., Vasseur V., Vacher R., Fremond C., Shebzukhov Y., Yeremeev V.V., et al. Partial redundancy of the pattern recognition receptors, scavenger receptors, and C-type lectins for the long-term control of Mycobacterium tuberculosis infection. J Immunol 2010, 184:7057-7070.
148. Matsumoto M., Tanaka T., Kaisho T., Sanjo H., Copeland N.G., Gilbert D.J., et al. A novel LPS-inducible C-type lectin is a transcriptional target of NF-IL6 in macrophages. J Immunol 1999, 163:5039-5048.
149. Yamasaki S., Matsumoto M., Takeuchi O., Matsuzawa T., Ishikawa E., Sakuma M., et al. C-type lectin Mincle is an activating receptor for pathogenic fungus, Malassezia. Proc Natl Acad Sci U S A 2009, 106:1897-1902.
150. Yamasaki S., Ishikawa E., Sakuma M., Hara H., Ogata K., Saito T. Mincle is an ITAM-coupled activating receptor that senses damaged cells. Nat Immunol 2008, 9:1179-1188.
151. Ishikawa E., Ishikawa T., Morita Y.S., Toyonaga K., Yamada H., Takeuchi O., et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 2009, 206:2879-2888.
152. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol 2010, 184:2756-2760.
153. Taylor P.R., Brown G.D., Reid D.M., Willment J.A., Martinez-Pomares L., Gordon S., et al. The beta-glucan receptor, dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J Immunol 2002, 169:3876-3882.
154. Willment J.A., Lin H.H., Reid D.M., Taylor P.R., Williams D.L., Wong S.Y., et al. Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J Immunol 2003, 171:4569-4573.
155. Willment J.A., Marshall A.S., Reid D.M., Williams D.L., Wong S.Y., Gordon S., et al. The human beta-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur J Immunol 2005, 35:1539-1547.
156. Brown G.D. Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 2006, 6:33-43.
157. Tsoni S.V. Brown GD: beta-Glucans and dectin-1. Ann N Y Acad Sci 2008, 1143:45-60.
158. Yadav M., Schorey J.S. The β-glucan receptor Dectin-1 fucntions together with TLR2 to mediate macrophage activation by mycobacteria. Blood 2006, 108:3168-3175.
159. van de Veerdonk F.L., Teirlinck A.C., Kleinnijenhuis J., Kullberg B.J., van C.R., Van der Meer J.W., et al. Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1. J Leukoc Biol 2010, 88:227-232.
160. Betz B.E., Azad A.K., Morris J.D., Rajaram M.V. Schlesinger LS: beta-Glucans inhibit intracellular growth of Mycobacterium bovis BCG but not virulent Mycobacterium tuberculosis in human macrophages. Microb Pathog 2011, 51:233-242.
161. Lee H.M., Yuk J.M., Shin D.M., Jo E.K. Dectin-1 is inducible and plays an essential role for mycobacteria-induced innate immune responses in airway epithelial cells. J Clin Immunol 2009, 29:795-805.
162. Ariizumi K., Shen G.L., Shikano S., Ritter R., Zukas P., Edelbaum D., et al. Cloning of a second dendritic cell-associated C-type lectin (dectin-2) and its alternatively spliced isoforms. J Biol Chem 2000, 275:11957-11963.
163. Taylor P.R., Reid D.M., Heinsbroek S.E., Brown G.D., Gordon S., Wong S.Y. Dectin-2 is predominantly myeloid restricted and exhibits unique activation-dependent expression on maturing inflammatory monocytes elicited in vivo. Eur J Immunol 2005, 35:2163-2174.
164. Sato K., Yang X.L., Yudate T., Chung J.S., Wu J., Luby-Phelps K., et al. Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses. J Biol Chem 2006, 281:38854-38866.
165. Yonekawa A., Saijo S., Hoshino Y., Miyake Y., Ishikawa E., Suzukawa M., et al. Dectin-2 Is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. Immunity 2014, 41:1-12.
166. Ting J.P., Duncan J.A., Lei Y. How the noninflammasome NLRs function in the innate immune system. Science 2010, 327:286-290.
167. Franchi L., Warner N., Viani K., Nunez G. Function of Nod-like receptors in microbial recognition and host defense. Immunol Rev 2009, 227:106-128.
168. Philpott D.J., Sorbara M.T., Robertson S.J., Croitoru K., Girardin S.E. NOD proteins: regulators of inflammation in health and disease. Nat Rev Immunol 2014, 14:9-23.
169. Hansen J.M., Golchin S.A., Veyrier F.J., Domenech P., Boneca I.G., Azad A.K., et al. N-glycolylated peptidoglycan contributes to the immunogenicity but not pathogenicity of Mycobacterium tuberculosis. J Infect Dis 2014, 209:1045-1054.
170. Coulombe F., Divangahi M., Veyrier F., de Léséleuc L., Gleason J.L., Yang Y., et al. Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 2009, 206:1709-1716.
171. Brooks M.N., Rajaram M.V., Azad A.K., Amer A.O., Valdivia-Arenas M.A., Park J.H., et al. NOD2 controls the nature of the inflammatory response and subsequent fate of Mycobacterium tuberculosis and M. bovis BCG in human macrophages. Cell Microbiol 2011, 13:402-418.
172. Juarez E., Carranza C., Hernandez-Sanchez F., Leon-Contreras J.C., Hernandez-Pando R., Escobedo D., et al. NOD2 enhances the innate response of alveolar macrophages to Mycobacterium tuberculosis in humans. Eur J Immunol 2012, 42:880-889.
173. Jiang-Shieh Y.F., Chien H.F., Chang C.Y., Wei T.S., Chiu M.M., Chen H.M., et al. Distribution and expression of CD200 in the rat respiratory system under normal and endotoxin-induced pathological conditions. J Anat 2010, 216:407-416.
174. Carow B., Rottenberg M.E. SOCS3, a major regulator of infection and inflammation. Front Immunol 2014, 5:58.
175. Vazquez N., Greenwell-Wild T., Rekka S., Orenstein J.M., Wahl S.M. Mycobacterium avium-induced SOCS contributes to resistance to IFN-gamma-mediated mycobactericidal activity in human macrophages. J Leukoc Biol 2006, 80:1136-1144.
176. Carow B., Ye X., Gavier-Widen D., Bhuju S., Oehlmann W., Singh M., et al. Silencing suppressor of cytokine signaling-1 (SOCS1) in macrophages improves Mycobacterium tuberculosis control in an interferon-gamma (IFN-gamma)-dependent manner. J Biol Chem 2011, 286:26873-26887.
177. Srivastava V., Vashishta M., Gupta S., Singla R., Singla N., Behera D., et al. Suppressors of cytokine signaling inhibit effector T cell responses during Mycobacterium tuberculosis infection. Immunol Cell Biol 2011, 89:786-791.
178. Srivastava V., Manchanda M., Gupta S., Singla R., Behera D., Das G., et al. Toll-like receptor 2 and DC-SIGNR1 differentially regulate suppressors of cytokine signaling 1 in dendritic cells during Mycobacterium tuberculosis infection. J Biol Chem 2009, 284:25532-25541.
179. Deng J.C., Cheng G., Newstead M.W., Zeng X., Kobayashi K., Flavell R.A., et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 2006, 116:2532-2542.
180. Kobayashi K., Hernandez L.D., Galan J.E., Janeway C.A., Medzhitov R., Flavell R.A. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002, 110:191-202.
181. Nakayama K., Okugawa S., Yanagimoto S., Kitazawa T., Tsukada K., Kawada M., et al. Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages. J Biol Chem 2004, 279:6629-6634.
182. Pathak S.K., Basu S., Bhattacharyya A., Pathak S., Kundu M., Basu J. Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages. J Biol Chem 2005, 280:42794-42800.
183. Jeyanathan M., McCormick S., Lai R., Afkhami S., Shaler C.R., Horvath C.N., et al. Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells. Mucosal Immunol 2014, 7:670-683.
184. Palmer D.C., Restifo N.P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol 2009, 30:592-602.
185. Delgado-Ortega M., Marc D., Dupont J., Trapp S., Berri M., Meurens F. SOCS proteins in infectious diseases of mammals. Vet Immunol Immunopathol 2013, 151:1-19.
186. Carow B., Reuschl A.K., Gavier-Widen D., Jenkins B.J., Ernst M., Yoshimura A., et al. Critical and independent role for SOCS3 in either myeloid or T cells in resistance to Mycobacterium tuberculosis. PLoS Pathog 2013, 9:e1003442.
187. Masood K.I., Rottenberg M.E., Salahuddin N., Irfan M., Rao N., Carow B., et al. Expression of M. tuberculosis-induced suppressor of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and secretion of IL-6 associates with differing clinical severity of tuberculosis. BMC Infect Dis 2013, 13:13.
188. Masood K.I., Rottenberg M.E., Carow B., Rao N., Ashraf M., Hussain R., et al. SOCS1 gene expression is increased in severe pulmonary tuberculosis. Scand J Immunol 2012, 76:398-404.
189. Wright G.J., Cherwinski H., Foster-Cuevas M., Brooke G., Puklavec M.J., Bigler M., et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003, 171:3034-3046.
190. Cherwinski H.M., Murphy C.A., Joyce B.L., Bigler M.E., Song Y.S., Zurawski S.M., et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol 2005, 174:1348-1356.
191. Shiratori I., Yamaguchi M., Suzukawa M., Yamamoto K., Lanier L.L., Saito T., et al. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J Immunol 2005, 175:4441-4449.
192. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991, 147:3815-3822.
193. Li L., Elliott J.F., Mosmann T.R. IL-10 inhibits cytokine production, vascular leakage, and swelling during T helper 1 cell-induced delayed-type hypersensitivity. J Immunol 1994, 153:3967-3978.
194. Moore K.W., O'Garra A., De Waal Malefyt R., Vieira P., Mosmann T.R. Interleukin-10. Annu Rev Immunol 1993, 11:165-190.
195. Asadullah K., Sterry W., VolK H.D. Interleukin-10 therapy - review of a new approach. Pharmacol Rev 2003, 55:241-269.
196. Moore K.W., de Waal M.R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
197. Schottelius A.J., Mayo M.W., Sartor R.B., Baldwin A.S. Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 1999, 274:31868-31874.
198. Yamaoka K., Otsuka T., Niiro H., Nakashima H., Tanaka Y., Nagano S., et al. Selective DNA-binding activity of interleukin-10-stimulated STAT molecules in human monocytes. J Interferon Cytokine Res 1999, 19:679-685.
199. Ito S., Ansari P., Sakatsume M., Dickensheets H., Vazquez N., Donnelly R.P., et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999, 93:1456-1463.
200. Cassatella M.A., Gasperini S., Bovolenta C., Calzetti F., Vollebregt M., Scapini P., et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 1999, 94:2880-2889.
201. Almeida A.S., Lago P.M., Boechat N., Huard R.C., Lazzarini L.C., Santos A.R., et al. Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 2009, 183:718-731.
202. Bonecini-Almeida M.G., Ho J.L., Boechat N., Huard R.C., Chitale S., Doo H., et al. Down-modulation of lung immune responses by interleukin-10 and transforming growth factor beta (TGF-beta) and analysis of TGF-beta receptors I and II in active tuberculosis. Infect Immun 2004, 72:2628-2634.
203. Verbon A., Juffermans N., van Deventer S.J., Speelman P., van D.H., Van der Poll T. Serum concentrations of cytokines in patients with active tuberculosis (TB) and after treatment. Clin Exp Immunol 1999, 115:110-113.
204. Gong J.H., Zhang M., Modlin R.L., Linsley P.S., Iyer D., Lin Y.G., et al. Interleukin-10 downregulates Mycobacterium tuberculosis- induced Th1 responses and CTLA-4 expression. Infect Immun 1996, 64:913-918.
205. Zhang M., Lin Y., Iyer D.V., Gong J., Abrams J.S., Barnes P.F. T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun 1995, 63:3231-3234.
206. Zhang M., Gong J., Iyer D.V., Jones B.E., Modlin R.L., Barnes P.F. T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest 1994, 94:2435-2442.
207. Boussiotis V.A., Tsai E.Y., Yunis E.J., Thim S., Delgado J.C., Dascher C.C., et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000, 105:1317-1325.
208. Huard R.C., Chitale S., Leung M., Lazzarini L.C., Zhu H., Shashkina E., et al. The Mycobacterium tuberculosis complex-restricted gene cfp32 encodes an expressed protein that is detectable in tuberculosis patients and is positively correlated with pulmonary interleukin-10. Infect Immun 2003, 71:6871-6883.
209. O'Leary S., O'Sullivan M.P., Keane J. IL-10 blocks phagosome maturation in Mycobacterium tuberculosis-infected human macrophages. Am J Respir Cell Mol Biol 2010, 45(1):172-180.
210. Pacheco A.G., Cardoso C.C., Moraes M.O. IFNG +874 T/A, IL10-1082G/A and TNF -308G/A polymorphisms in association with tuberculosis susceptibility: a meta-analysis study. Hum Genet 2008, 123:477-484.
211. Ates O., Musellim B., Ongen G., Topal-Sarikaya A. Interleukin-10 and tumor necrosis factor-alpha gene polymorphisms in tuberculosis. J Clin Immunol 2008, 28:232-236.
212. Oral H.B., Budak F., Uzaslan E.K., Basturk B., Bekar A., Akalin H., et al. Interleukin-10 (IL-10) gene polymorphism as a potential host susceptibility factor in tuberculosis. Cytokine 2006, 35:143-147.
213. North R.J. Mice incapable of making IL-4 or IL-10 display normal resistance to infection with Mycobacterium tuberculosis. Clin Exp Immunol 1998, 113:55-58.
214. Jung Y.J., Ryan L., LaCourse R., North R.J. Increased interleukin-10 expression is not responsible for failure of T helper 1 immunity to resolve airborne Mycobacterium tuberculosis infection in mice. Immunology 2003, 109:295-299.
215. Higgins D.M., Sanchez-Campillo J., Rosas-Taraco A.G., Lee E.J., Orme I.M., Gonzalez-Juarrero M. Lack of IL-10 alters inflammatory and immune responses during pulmonary Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2009, 89:149-157.
216. Redford P.S., Boonstra A., Read S., Pitt J., Graham C., Stavropoulos E., et al. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 2010, 40:2200-2210.
217. Roach D.R., Martin E., Bean A.G., Rennick D.M., Briscoe H., Britton W.J. Endogenous inhibition of antimycobacterial immunity by IL-10 varies between mycobacterial species. Scand J Immunol 2001, 54:163-170.
218. Beamer G.L., Flaherty D.K., Assogba B.D., Stromberg P., Gonzalez-Juarrero M., de Waal M.R., et al. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol 2008, 181:5545-5550.
219. Turner J., Gonzalez-Juarrero M., Ellis D.L., Basaraba R.J., Kipnis A., Orme I.M., et al. In vivo IL-10 production reactivates chronic pulmonary tuberculosis in C57BL/6 mice. J Immunol 2002, 169:6343-6351.
220. Sendide K., Deghmane A.E., Pechkovsky D., Av-Gay Y., Talal A., Hmama Z. Mycobacterium bovis BCG attenuates surface expression of mature class II molecules through IL-10-dependent inhibition of cathepsin S. J Immunol 2005, 175:5324-5332.
221. Pitt J.M., Stavropoulos E., Redford P.S., Beebe A.M., Bancroft G.J., Young D.B., et al. Blockade of IL-10 signaling during bacillus Calmette-Guerin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-gamma and IL-17 responses and increases protection to Mycobacterium tuberculosis infection. J Immunol 2012, 189:4079-4087.
222. Mayer-Barber K.D., Andrade B.B., Barber D.L., Hieny S., Feng C.G., Caspar P., et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity 2011, 35:1023-1034.
223. O'Garra A., Redford P.S., McNab F.W., Bloom C.I., Wilkinson R.J., Berry M.P. The immune response in tuberculosis. Annu Rev Immunol 2013, 31:475-527.
224. Simmons D.P., Canaday D.H., Liu Y., Li Q., Huang A., Boom W.H., et al. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J Immunol 2010, 185:2405-2415.
225. Manca C., Tsenova L., Bergtold A., Freeman S., Tovey M., Musser J.M., et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/B. Proc Natl Acad Sci USA 2001, 98:5752-5757.
226. Stanley S.A., Johndrow J.E., Manzanillo P., Cox J.S. The type I IFN response to infection with Mycobacterium tuberculosis requires ESX-1-mediated secretion and contributes to pathogenesis. J Immunol 2007, 178:3143-3152.
227. Antonelli L.R., Gigliotti R.A., Goncalves R., Roffe E., Cheever A.W., Bafica A., et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest 2010, 120:1674-1682.
228. Watson R.O., Manzanillo P.S., Cox J.S. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell 2012, 150:803-815.
229. Berry M.P., Graham C.M., McNab F.W., Xu Z., Bloch S.A., Oni T., et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010, 466:973-977.
230. Teles R.M., Graeber T.G., Krutzik S.R., Montoya D., Schenk M., Lee D.J., et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 2013, 339:1448-1453.
231. Mayer-Barber K.D., Andrade B.B., Oland S.D., Amaral E.P., Barber D.L., Gonzales J., et al. Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk. Nature 2014, 511:99-103.
232. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
233. Ricote M., Huang J.T., Welch J.S., Glass C.K. The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999, 66:733-739.
234. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
235. von Knethen A., Brune B. Activation of peroxisome proliferator-activated receptor gamma by nitric oxide in monocytes/macrophages down-regulates p47phox and attenuates the respiratory burst. J Immunol 2002, 169:2619-2626.
236. Ahmadian M., Suh J.M., Hah N., Liddle C., Atkins A.R., Downes M., et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med 2013, 19:557-566.
237. Malur A., Mccoy A.J., Arce S., Barna B.P., Kavuru M.S., Malur A.G., et al. Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol 2009, 182:5816-5822.
238. Almeida P.E., Silva A.R., Maya-Monteiro C.M., Torocsik D., D'Avila H., Dezso B., et al. Mycobacterium bovis bacillus Calmette-Guerin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis. J Immunol 2009, 183:1337-1345.
239. Repa J.J., Mangelsdorf D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol 2000, 16:459-481.
240. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003, 9:213-219.
241. Ricote M., Valledor A.F., Glass C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:230-239.
242. Valledor A.F. The innate immune response under the control of the LXR pathway. Immunobiology 2005, 210:127-132.
243. Mitro N., Mak P.A., Vargas L., Godio C., Hampton E., Molteni V., et al. The nuclear receptor LXR is a glucose sensor. Nature 2007, 445:219-223.
244. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat Med 2002, 8:1243-1248.
245. Russell D.G., Cardona P.J., Kim M.J., Allain S., Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009, 10:943-948.
246. Daniel J., Maamar H., Deb C., Sirakova T.D., Kolattukudy P.E. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog 2011, 7:e1002093.
247. Gatfield J., Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 2000, 288:1647-1650.
248. Korf H., Vander B.S., Romano M., Steffensen K.R., Stijlemans B., Gustafsson J.A., et al. Liver X receptors contribute to the protective immune response against Mycobacterium tuberculosis in mice. J Clin Invest 2009, 119:1626-1637.
249. Han M., Liang L., Liu L.R., Yue J., Zhao Y.L., Xiao H.P. Liver X receptor gene polymorphisms in tuberculosis: effect on susceptibility. PLOS ONE 2014, 9:e95954.
250. Chang C., Da Silva S.L., Ideta R., Lee Y., Yeh S., Burbach J.P. Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily. Proc Natl Acad Sci U S A 1994, 91:6040-6044.
251. Lee Y.F., Lee H.J., Chang C. Recent advances in the TR2 and TR4 orphan receptors of the nuclear receptor superfamily. J Steroid Biochem Mol Biol 2002, 81:291-308.
252. Xie S., Lee Y.F., Kim E., Chen L.M., Ni J., Fang L.Y., et al. TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Natl Acad Sci U S A 2009, 106:13353-13358.
253. Dkhar H.K., Nanduri R., Mahajan S., Dave S., Saini A., Somavarapu A.K., et al. Mycobacterium tuberculosis keto-mycolic acid and macrophage nuclear receptor TR4 modulate foamy biogenesis in granulomas: a case of a heterologous and noncanonical ligand-receptor pair. J Immunol 2014, 193:295-305.
254. Rajaram M.V., Ni B., Morris J.D., Brooks M.N., Carlson T.K., Bakthavachalu B., et al. Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b. Proc Natl Acad Sci U S A 2011, 108:17408-17413.
255. Torrelles J.B., Sieling P.A., Arcos J., Knaup R., Bartling C., Rajaram M.V., et al. Structural differences in lipomannans from pathogenic and nonpathogenic mycobacteria that impact CD1b-restricted T cell responses. J Biol Chem 2011, 286:35438-35446.
256. Lee W., VanderVen B.C., Fahey R.J., Russell D.G. Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 2013, 288(10):6788-6800.
257. Harizi H., Corcuff J.B., Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology and immunopathology. Trends Mol Med 2008, 14(10):461-469.
258. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011, 31:986-1000.
259. Ueno N., Murakami M., Tanioka T., Fujimori K., Tanabe T., Urade Y., et al. Coupling between cyclooxygenase, terminal prostanoid synthase, and phospholipase A2. J Biol Chem 2001, 276:34918-34927.
260. Aoki T., Narumiya S. Prostaglandins and chronic inflammation. Trends Pharmacol Sci 2012, 33:304-311.
261. Coceani F., Bishai I., Lees J., Sirko S. Prostaglandin E2 and fever. A continuing debate. Yale J Biol Med 1986, 59:169-174.
262. Scher J.U., Pillinger M.H. 15d-PGJ2: the anti-inflammatory prostaglandin. Clin Immunol 2005, 114:100-109.
263. Rangel M.J., Estrada G., De La Luz Garcia Hernandez I., Aguilar L.D., Marquez R., Hernandez P.R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology 2002, 106:257-266.
264. Sreeramkumar V., Fresno M., Cuesta N. Prostaglandin E2 and T cells: friends or foes?. Immunol Cell Biol 2012, 90:579-586.
265. Russell C.D., Schwarze J. The role of pro-resolution lipid mediators in infectious disease. Immunology 2014, 141:166-173.
266. Bafica A., Scanga C.A., Serhan C., Machado F., White S., Sher A., et al. Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production. J Clin Invest 2005, 115:1601-1606.
267. Widgerow A.D. Cellular resolution of inflammation - catabasis. Wound Repair Regen 2012, 20:2-7.
268. Fiore S., Serhan C.N. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry 1995, 34:16678-16686.
269. Ye Y., Lin Y., Perez-Polo J.R., Uretsky B.F., Ye Z., Tieu B.C., et al. Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production. J Immunol 2008, 181:3515-3523.
270. Birnbaum Y., Ye Y., Lin Y., Freeberg S.Y., Nishi S.P., Martinez J.D., et al. Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat. Circulation 2006, 114:929-935.
271. Divangahi M., Chen M., Gan H., Desjardins D., Hickman T.T., Lee D.M., et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009, 10:899-906.
272. Kowal-Bielecka O., Kowal K., Distler O., Gay S. Mechanisms of disease: leukotrienes and lipoxins in scleroderma lung disease - insights and potential therapeutic implications. Nat Clin Pract Rheumatol 2007, 3:43-51.
273. Ford-Hutchinson A., Letts G. Biological actions of leukotrienes. State of the art lecture. Hypertension 1986, 8:II44-II49.
274. Peters-Golden M., Henderson W.R. Leukotrienes. N Engl J Med 2007, 357:1841-1854.
275. Drazen J.M., Israel E., O'Byrne P.M. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999, 340:197-206.
276. Kim N.D., Chou R.C., Seung E., Tager A.M., Luster A.D. A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis. J Exp Med 2006, 203:829-835.
277. Peres-Buzalaf C., de P.L., Frantz F.G., Soares E.M., Medeiros A.I., Peters-Golden M., et al. Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins. Prostaglandins Leukot Essent Fatty Acids 2011, 85:75-81.
278. Coffey M.J., Phare S.M., Peters-Golden M. Role of leukotrienes in killing of Mycobacterium bovis by neutrophils. Prostaglandins Leukot Essent Fatty Acids 2004, 71:185-190.
279. Franco L.H., Paula M.O., Wowk P.F., Fonseca D.M., Sergio C.A., Fedatto P.F., et al. Leukotrienes are not essential for the efficacy of a heterologous vaccine against Mycobacterium tuberculosis infection. Braz J Med Biol Res 2010, 43:645-650.
280. El-Ahmady O., Mansour M., Zoeir H., Mansour O. Elevated concentrations of interleukins and leukotriene in response to Mycobacterium tuberculosis infection. Ann Clin Biochem 1997, 34(Pt 2):160-164.
281. Tobin D.M., Roca F.J., Oh S.F., McFarland R., Vickery T.W., Ray J.P., et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012, 148:434-446.
282. Tobin D.M., Roca F.J., Ray J.P., Ko D.C., Ramakrishnan L. An enzyme that inactivates the inflammatory mediator leukotriene b4 restricts mycobacterial infection. PLOS ONE 2013, 8:e67828.
283. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
284. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
285. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
286. Yi Z., Fu Y., Ji R., Li R., Guan Z. Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. PLoS ONE 2012, 7:e43184.
287. Miotto P., Mwangoka G., Valente I.C., Norbis L., Sotgiu G., Bosu R., et al. miRNA signatures in Sera of patients with active pulmonary tuberculosis. PLOS ONE 2013, 8:e80149.
288. Zhang X., Guo J., Fan S., Li Y., Wei L., Yang X., et al. Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis. PLOS ONE 2013, 8:e81076.
289. Qi Y., Cui L., Ge Y., Shi Z., Zhao K., Guo X., et al. Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infect Dis 2012, 12:384.
290. Fu Y., Yi Z., Wu X., Li J., Xu F. Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol 2011, 49:4246-4251.
291. Wang J., Yang K., Zhou L., Minhaowu Wu Y., Zhu M., et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog 2013, 9:e1003697.
292. Kumar R., Halder P., Sahu S.K., Kumar M., Kumari M., Jana K., et al. Identification of a novel role of ESAT-6-dependent miR-155 induction during infection of macrophages with Mycobacterium tuberculosis. Cell Microbiol 2012, 14:1620-1631.
293. Singh Y., Kaul V., Mehra A., Chatterjee S., Tousif S., Dwivedi V.P., et al. Mycobacterium tuberculosis controls microRNA-99b (miR-99b) expression in infected murine dendritic cells to modulate host immunity. J Biol Chem 2013, 288:5056-5061.
294. Liu Y., Wang X., Jiang J., Cao Z., Yang B., Cheng X. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Mol Immunol 2011, 48:1084-1090.
295. Park S.Y., Lee J.H., Ha M., Nam J.W., Kim V.N. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009, 16:23-29.
296. Ma F., Xu S., Liu X., Zhang Q., Xu X., Liu M., et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 2011, 12:861-869.
297. Ma C., Li Y., Li M., Deng G., Wu X., Zeng J., et al. microRNA-124 negatively regulates TLR signaling in alveolar macrophages in response to mycobacterial infection. Mol Immunol 2014, 62:150-158.
298. Liu G., Friggeri A., Yang Y., Park Y.J., Tsuruta Y., Abraham E. miR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses. Proc Natl Acad Sci U S A 2009, 106:15819-15824.
299. Wang J., Yang K., Zhou L., Minhaowu, Wu Y., Zhu M., et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. PLoS Pathog 2013, 9:e1003697.
300. Dorhoi A., Iannaccone M., Farinacci M., Fae K.C., Schreiber J., Moura-Alves P., et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest 2013, 123(11):4836-4848.
301. Heuts F., Gavier-Widen D., Carow B., Juarez J., Wigzell H., Rottenberg M.E. CD4+ cell-dependent granuloma formation in humanized mice infected with mycobacteria. Proc Natl Acad Sci U S A 2013, 110:6482-6487.
302. Mestas J., Hughes C.C. Of mice and not men differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
303. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., et al. A network-based analysis of systemic inflammation in humans. Nature 2005, 437:1032-1037.
304. He L.Z., Crocker A., Lee J., Mendoza-Ramirez J., Wang X.T., Vitale L.A., et al. Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol 2007, 178:6259-6267.
305. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
306. Copeland S., Warren H.S., Lowry S.F., Calvano S.E., Remick D. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005, 12:60-67.
307. Risso A. Leukocyte antimicrobial peptides: multifunctional effector molecules of innate immunity. J Leukoc Biol 2000, 68:785-792.
308. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001, 2:907-916.
309. Weinberg J.B. Nitric oxide production and nitric oxide synthase type 2 expression by human mononuclear phagocytes: a review. Mol Med 1998, 4:557-591.
310. Restrepo B.I., Twahirwa M., Rahbar M.H., Schlesinger L.S. Phagocytosis via complement or Fc-gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia. PLOS ONE 2014, 9:e92977.